Gilead Sciences Inc
GILD Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Forecast
Insiders
Institutions
Government
Ownership
News
$GILD is featured in our Rob Bresnahan and Shelley Moore Capito strategies.
All StrategiesIncome
Balance Sheet
Cash Flow
Revenue Breakdown
Recent trades of GILD by members of U.S. Congress
GILD Stock Insider Trading Activity
Follow @QuiverQuant for major insider updates
Closing Price
Purchase
Sale
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
GILD Stock Institutional Owners
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
GILD Derivatives Institutional Owners
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in GILD holdings by institutional investors
Quarterly net insider trading by GILD's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Backtest Start Date
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Subscribe to Quiver Premium for insider trading alerts
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$2,780,000 Oct 20, 2025 Issue: Trade (domestic/foreign) Health Issues Medicare/Medicaid Copyright/Patent/Trademark Budget/Appropriations Taxation/Internal Revenue Code
-
$1,700,000 Jul 21, 2025 Issue: Health Issues Trade (domestic/foreign) Medicare/Medicaid Copyright/Patent/Trademark Budget/Appropriations Taxation/Internal Revenue Code
-
$1,662,000 Apr 21, 2025 Issue: Trade (domestic/foreign) Health Issues Medicare/Medicaid Copyright/Patent/Trademark Budget/Appropriations Taxation/Internal Revenue Code
-
$2,440,000 Jan 21, 2025 Issue: Trade (domestic/foreign) Health Issues Medicare/Medicaid Copyright/Patent/Trademark Budget/Appropriations Taxation/Internal Revenue Code
-
$2,050,000 Oct 21, 2024 Issue: Taxation/Internal Revenue Code Budget/Appropriations Copyright/Patent/Trademark Medicare/Medicaid Health Issues Trade (domestic/foreign)
-
$1,530,000 Jul 22, 2024 Issue: Taxation/Internal Revenue Code Budget/Appropriations Copyright/Patent/Trademark Medicare/Medicaid Health Issues Trade (domestic/foreign)
-
$2,740,000 Apr 18, 2024 Issue: Taxation/Internal Revenue Code Budget/Appropriations Copyright/Patent/Trademark Medicare/Medicaid Health Issues Trade (domestic/foreign)
-
$1,680,000 Jan 23, 2024 Issue: Taxation/Internal Revenue Code Budget/Appropriations Copyright/Patent/Trademark Medicare/Medicaid Health Issues Trade (domestic/foreign)
-
$2,390,000 Oct 20, 2023 Issue: Taxation/Internal Revenue Code Budget/Appropriations Copyright/Patent/Trademark Medicare/Medicaid Health Issues Trade (domestic/foreign)
-
$1,440,000 Jul 20, 2023 Issue: Taxation/Internal Revenue Code Budget/Appropriations Copyright/Patent/Trademark Medicare/Medicaid Health Issues Trade (domestic/foreign)
-
$1,490,000 Apr 14, 2023 Issue: Taxation/Internal Revenue Code Budget/Appropriations Copyright/Patent/Trademark Medicare/Medicaid Health Issues Trade (domestic/foreign)
-
$2,520,000 Oct 20, 2022 Issue: Taxation/Internal Revenue Code Budget/Appropriations Copyright/Patent/Trademark Medicare/Medicaid Health Issues Trade (domestic/foreign)
-
$1,372,000 Jul 20, 2022 Issue: Taxation/Internal Revenue Code Budget/Appropriations Copyright/Patent/Trademark Medicare/Medicaid Health Issues Trade (domestic/foreign)
-
$2,620,000 Apr 20, 2022 Issue: Taxation/Internal Revenue Code Budget/Appropriations Copyright/Patent/Trademark Medicare/Medicaid Health Issues Trade (domestic/foreign)
-
$1,980,000 Jan 19, 2022 Issue: None
-
$2,290,000 Oct 20, 2021 Issue: None
-
$1,380,000 Jul 20, 2021 Issue: None
-
$2,530,000 Apr 20, 2021 Issue: None
-
$1,510,000 Jan 20, 2021 Issue: None
-
$1,810,000 Oct 20, 2020 Issue: None
-
$1,260,000 Jul 20, 2020 Issue: None
-
$2,450,000 Apr 20, 2020 Issue: None
-
$1,300,000 Jan 21, 2020 Issue: None
-
$1,480,000 Oct 21, 2019 Issue: Budget/Appropriations Medicare/Medicaid Veterans Health Issues Taxation/Internal Revenue Code Copyright/Patent/Trademark Trade (domestic/foreign)
-
$1,080,000 Jul 22, 2019 Issue: Indian/Native American Affairs Budget/Appropriations Medicare/Medicaid Veterans Health Issues Copyright/Patent/Trademark Trade (domestic/foreign) Taxation/Internal Revenue Code
-
$1,860,000 Apr 23, 2019 Issue: Indian/Native American Affairs Budget/Appropriations Medicare/Medicaid Trade (domestic/foreign) Taxation/Internal Revenue Code Veterans Copyright/Patent/Trademark Health Issues
-
$700,000 Jan 22, 2019 Issue: Medicare/Medicaid Defense Trade (domestic/foreign) Copyright/Patent/Trademark Health Issues Veterans Budget/Appropriations Indian/Native American Affairs Taxation/Internal Revenue Code
-
$680,000 Oct 22, 2018 Issue: Medicare/Medicaid Veterans Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Trade (domestic/foreign) Indian/Native American Affairs Budget/Appropriations
-
$800,000 Jul 20, 2018 Issue: Indian/Native American Affairs Budget/Appropriations Medicare/Medicaid Foreign Relations Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Veterans Trade (domestic/foreign)
-
$810,000 Apr 20, 2018 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Trade (domestic/foreign) Veterans Foreign Relations Indian/Native American Affairs Budget/Appropriations Taxation/Internal Revenue Code
-
$900,000 Jan 22, 2018 Issue: Indian/Native American Affairs Budget/Appropriations Medicare/Medicaid Health Issues Copyright/Patent/Trademark Trade (domestic/foreign) Taxation/Internal Revenue Code Veterans Foreign Relations
-
$810,000 Oct 20, 2017 Issue: Budget/Appropriations Medicare/Medicaid Health Issues Veterans Copyright/Patent/Trademark Foreign Relations Trade (domestic/foreign) Taxation/Internal Revenue Code Pharmacy Indian/Native American Affairs
-
$790,000 Jul 20, 2017 Issue: Pharmacy Budget/Appropriations Medicare/Medicaid Health Issues Copyright/Patent/Trademark Veterans Trade (domestic/foreign) Indian/Native American Affairs Foreign Relations Taxation/Internal Revenue Code
-
$1,050,000 Apr 20, 2017 Issue: Law Enforcement/Crime/Criminal Justice Pharmacy Medicare/Medicaid Foreign Relations Health Issues Copyright/Patent/Trademark Indian/Native American Affairs Veterans Trade (domestic/foreign) Taxation/Internal Revenue Code Budget/Appropriations
-
$960,000 Jan 19, 2017 Issue: Medicare/Medicaid Veterans Health Issues Copyright/Patent/Trademark Budget/Appropriations Foreign Relations Trade (domestic/foreign) Law Enforcement/Crime/Criminal Justice Pharmacy
-
$780,000 Oct 20, 2016 Issue: Law Enforcement/Crime/Criminal Justice Pharmacy Medicare/Medicaid Foreign Relations Veterans Health Issues Copyright/Patent/Trademark Budget/Appropriations Trade (domestic/foreign) Defense
-
$760,000 Jul 19, 2016 Issue: Medicare/Medicaid Foreign Relations Health Issues Pharmacy Trade (domestic/foreign) Veterans Defense Budget/Appropriations Copyright/Patent/Trademark
-
$980,000 Apr 18, 2016 Issue: Science/Technology Pharmacy Medicare/Medicaid Foreign Relations Veterans Health Issues Trade (domestic/foreign) Defense Budget/Appropriations Copyright/Patent/Trademark
-
$890,000 Jan 20, 2016 Issue: Science/Technology Pharmacy Medicare/Medicaid Health Issues Trade (domestic/foreign) Copyright/Patent/Trademark Veterans Foreign Relations Defense Budget/Appropriations
-
$700,000 Oct 19, 2015 Issue: Pharmacy Medicare/Medicaid Veterans Health Issues Defense Trade (domestic/foreign) Foreign Relations Budget/Appropriations Copyright/Patent/Trademark Science/Technology
-
$550,000 Jul 20, 2015 Issue: Science/Technology Pharmacy Medicare/Medicaid Veterans Health Issues Copyright/Patent/Trademark Defense Foreign Relations Budget/Appropriations Trade (domestic/foreign)
-
$800,000 Apr 21, 2015 Issue: Medicare/Medicaid Health Issues Veterans Trade (domestic/foreign) Defense Copyright/Patent/Trademark
-
$620,000 Jan 19, 2015 Issue: Medicare/Medicaid Health Issues Veterans Trade (domestic/foreign) Defense Copyright/Patent/Trademark
-
$640,000 Oct 17, 2014 Issue: Medicare/Medicaid Health Issues Veterans Trade (domestic/foreign) Copyright/Patent/Trademark
-
$820,000 Jul 15, 2014 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Trade (domestic/foreign)
-
$810,000 Apr 18, 2014 Issue: Medicare/Medicaid Veterans Health Issues Trade (domestic/foreign) Copyright/Patent/Trademark
-
$550,000 Jan 21, 2014 Issue: Health Issues Copyright/Patent/Trademark Veterans Medicare/Medicaid
-
$540,000 Oct 21, 2013 Issue: Health Issues Copyright/Patent/Trademark Veterans Medicare/Medicaid
-
$623,000 Aug 05, 2013 Issue: Health Issues Copyright/Patent/Trademark
-
$510,000 Jul 19, 2013 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Trade (domestic/foreign)
-
$320,000 Jan 22, 2013 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark
-
$370,000 Oct 22, 2012 Issue: Health Issues
-
$340,000 Jul 20, 2012 Issue: Health Issues
-
$560,000 Apr 20, 2012 Issue: Health Issues
-
$400,000 Jan 20, 2012 Issue: Health Issues
-
$370,000 Oct 20, 2011 Issue: Health Issues
-
$390,000 Jul 20, 2011 Issue: Health Issues
-
$500,000 Apr 20, 2011 Issue: Health Issues
-
$340,000 Jan 20, 2011 Issue: Health Issues
-
$350,000 Oct 20, 2010 Issue: Health Issues
-
$350,000 Jul 20, 2010 Issue: Health Issues
-
$480,000 Apr 20, 2010 Issue: Health Issues
-
$370,000 Jan 20, 2010 Issue: Health Issues
-
$350,000 Oct 20, 2009 Issue: Health Issues
-
$290,000 Jul 20, 2009 Issue: Health Issues
-
$270,000 Apr 20, 2009 Issue: Health Issues
-
$240,000 Jan 09, 2009 Issue: Health Issues
-
$240,000 Oct 28, 2008 Issue: Health Issues
-
$260,000 Oct 28, 2008 Issue: Health Issues
-
$260,000 Jun 25, 2008 Issue: Health Issues
-
$280,000 Feb 14, 2008 Issue: Health Issues
-
$380,000 Aug 14, 2007 Issue: Health Issues
-
$355,000 Feb 13, 2007 Issue: Health Issues
-
$455,000 Aug 14, 2006 Issue: Health Issues
-
$180,000 Apr 06, 2006 Issue: Health Issues
-
$60,000 Aug 24, 2005 Issue: Medical/Disease Research/Clinical Labs
-
$140,000 Aug 22, 2005 Issue: Health Issues
-
$20,000 Aug 15, 2005 Issue: Trade (domestic/foreign)
-
$40,000 Feb 09, 2005 Issue: None
-
$40,000 Sep 08, 2004 Issue: Health Issues
-
$100,000 Apr 12, 2004 Issue: Health Issues Pharmacy
-
$100,000 Aug 15, 2003 Issue: Health Issues Pharmacy
-
$100,000 Mar 03, 2003 Issue: Health Issues Pharmacy
-
$100,000 Aug 14, 2002 Issue: Health Issues Pharmacy
-
$60,000 Feb 14, 2002 Issue: Health Issues Pharmacy
GILD Estimated quarterly lobbying spending
GILD Revenue by Segment or Geography
By Segment
By Geography
GILD Income Statement
GILD Balance Sheet
GILD Cash Flow
U.S. Patents
New GILD patent grants
-
Patent Title: Solid forms of an ask1 inhibitor May. 09, 2017
-
Patent Title: Macrocyclic inhibitors of May. 09, 2017
-
Patent Title: Polycyclic-carbamoylpyridone compounds and their pharmaceutical use Apr. 25, 2017
-
Patent Title: Isoquinoline compounds Apr. 18, 2017
-
Patent Title: Inhibitors of hepatitis c virus Apr. 11, 2017
-
Patent Title: 2′-chloro aminopyrimidinone and pyrimidine dione nucleosides Apr. 11, 2017
-
Patent Title: Modulators of toll-like receptor 7 Apr. 04, 2017
-
Patent Title: Inhibitors of histone demethylases Apr. 04, 2017
-
Patent Title: Inhibitors of histone demethylases Apr. 04, 2017
-
Patent Title: Compounds for the treatment of addiction Apr. 04, 2017
-
Patent Title: Fused heterocyclic compounds as ion channel modulators Mar. 21, 2017
-
Patent Title: Processes for preparing ask1 inhibitors Mar. 07, 2017
-
Patent Title: Apoptosis signal-regulating kinase inhibitors Mar. 07, 2017
-
Patent Title: Phosphonate analogs of hiv inhibitor compounds Feb. 28, 2017
-
Patent Title: Modulators of pharmacokinetic properties of therapeutics Feb. 21, 2017
-
Patent Title: Methods of preparing toll-like receptor modulators Feb. 21, 2017
-
Patent Title: Crystalline forms of an antiviral compound Feb. 07, 2017
-
Patent Title: Compositions and methods of treating pulmonary hypertension Jan. 24, 2017
-
Patent Title: Compounds for the treatment of hiv Jan. 10, 2017
-
Patent Title: Fxr (nr1h4) binding and activity modulating compounds Jan. 10, 2017
-
Patent Title: Inhalable aztreonam for treatment and prevention of pulmonary bacterial infections Jan. 03, 2017
-
Patent Title: Polycyclic-carbamoylpyridone compounds and their pharmaceutical use Dec. 20, 2016
-
Patent Title: Macrocyclic inhibitors of flaviviridae viruses Dec. 06, 2016
-
Patent Title: Compounds and methods for antiviral treatment Nov. 29, 2016
-
Patent Title: Method for treating a pulmonary hypertension condition Nov. 29, 2016
-
Patent Title: Syk inhibitors Nov. 29, 2016
-
Patent Title: Phosphatidylinositol 3-kinase inhibitors Nov. 22, 2016
-
Patent Title: Solid forms of tenofovir Nov. 08, 2016
-
Patent Title: Methods for the preparation of diasteromerically pure phosphoramidate prodrugs Nov. 08, 2016
-
Patent Title: 2′-substituted carba-nucleoside analogs for antiviral treatment Nov. 01, 2016
-
Patent Title: Method for treating a pulmonary hypertension condition Oct. 25, 2016
-
Patent Title: (n-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide Oct. 18, 2016
-
Patent Title: Therapeutic compounds Oct. 11, 2016
-
Patent Title: Methods of treating patients co-infected with hiv and tuberculosis Oct. 11, 2016
-
Patent Title: Substituted pyrido[1′,2′:4,5]pyrazino[1,2-a]azepines for treating viral infections Oct. 04, 2016
-
Patent Title: Benzimidazole derivatives as bromodomain inhibitors Oct. 04, 2016
-
Patent Title: Compositions and methods for combination antiviral therapy Oct. 04, 2016
-
Patent Title: Antiviral compounds Oct. 04, 2016
-
Patent Title: Modulators of toll-like receptors Sep. 27, 2016
-
Patent Title: Methods for treating hcv Sep. 27, 2016
-
Patent Title: Synthesis of an antiviral compound Sep. 13, 2016
-
Patent Title: Methods and intermediates for preparing pharmaceutical agents Aug. 30, 2016
-
Patent Title: Polycyclic-carbamoylpyridone compounds and their pharmaceutical use Aug. 23, 2016
-
Patent Title: Fused heterocyclic compounds as ion channel modulators Aug. 16, 2016
-
Patent Title: Fused heterocyclic compounds as ion channel modulators Aug. 02, 2016
-
Patent Title: Pyrrolo[1,2-f][1,2,4]triazines useful for treating respiratory syncitial virus infections Jul. 12, 2016
-
Patent Title: Salts of hiv inhibitor compounds Jul. 05, 2016
-
Patent Title: Substituted pyrrolidines as syk inhibitors Jun. 28, 2016
-
Patent Title: 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating aids Jun. 28, 2016
-
Patent Title: Fused heterocyclic compounds as ion channel modulators Jun. 21, 2016
Government Contracts
Federal grants, loans, and purchases
- $14,894 2025-05-14 00:00:00 Agency: Department of Veterans Affairs
- $3,882 2025-01-28 00:00:00 Agency: Department of Veterans Affairs
- $3,106 2025-01-23 00:00:00 Agency: Department of Veterans Affairs
- $14,938 2024-09-12 00:00:00 Agency: Department of Veterans Affairs
- $47,797 2024-06-26 00:00:00 Agency: Department of Veterans Affairs
- $47,797 2024-06-06 00:00:00 Agency: Department of Veterans Affairs
- $14,938 2024-04-15 00:00:00 Agency: Department of Veterans Affairs
- $307,511 2023-10-05 00:00:00 Agency: Department of Veterans Affairs
- $0 2022-09-27 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $287,923 2022-08-05 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $393,105 2022-07-08 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $38,673 2021-12-30 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $19,337 2021-12-23 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $284,905 2021-09-24 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $19,337 2021-09-10 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $284,905 2021-07-29 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $373,000 2021-07-13 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $34,806 2021-07-02 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $284,905 2021-06-01 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $284,905 2021-04-26 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $284,905 2021-03-16 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $77,850 2021-03-02 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $46,710 2021-02-24 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $58,388 2021-02-08 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $284,905 2021-02-02 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $77,850 2021-01-21 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $3,892,500 2021-01-20 00:00:00 Agency: DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS)
- $136,238 2021-01-19 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $284,905 2021-01-15 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $46,710 2021-01-12 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $194,625 2021-01-11 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $77,850 2021-01-08 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $155,700 2021-01-06 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $46,710 2021-01-05 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
Government Contracts
Estimated quarterly amount awarded to GILD from public contracts
GILD News
Recent insights relating to GILD
CNBC Recommendations
Recent picks made for GILD stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in GILD
GILD Analyst Ratings
GILD Stock Forecasts
...
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
GILD Analyst Forecasts
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
Frequently Asked Questions
- Is $GILD stock a Buy, Sell, or Hold?
- What is the price target for $GILD stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
GILD Top Shareholders
|
Shareholder
|
Shares Held
|
|---|
Frequently Asked Questions
- Who owns $GILD stock?
- Who owns the most shares of $GILD stock?
- What funds own $GILD stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
GILD Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view GILD Smart Score
Score Breakdown
Bull Case vs Bear Case
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
Bulls Say:
The Bulls Say summary highlights positive aspects of the stock.
Bears Say:
The Bears Say summary points out potential risks and negative aspects of the stock.
Show More
About GILD
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
- Address Foster City, CA
- Market Cap 157.1 billion
- Employees 17,600
- Industrial Classification Biological Products, (No Disgnostic Substances)